Next-generation drugs, diagnostics, and technologies to solve urgent medical needs
SRI Biosciences develops transformative approaches and platforms for challenging therapeutic problems. We conduct basic and translational research, have the breadth — and depth — to deliver the latest in biomedical research through technology development.
Our researchers have a rich legacy of collaboration with government agencies and industry partners that improve health outcomes and well-being around the world. SRI Biosciences projects range from high-impact, early-stage research to drug co-development with pharmaceutical and biotech companies.
200+Research and technical staff(40% PhDs)
200+Biomedical products moved to clinical trials
11Partnerships with National Institutes of Health Divisions
“Because we’re a nonprofit with a mission to make the world a better place, there’s a lot of flexibility in the types of projects we can pursue. We can do earlier stage research that may have higher impact without as much emphasis on the bottom line. And when we collaborate with pharmaceutical companies, it’s truly a co-development process—sharing expertise and innovating together.”
Kathlynn Brown, PhDPresident – Biosciences Division
New ways of thinking about human health
Uncommon in the world of tech development, SRI Biosciences brings together basic bioscience, applied research for early-stage IP generation, and translational development — moving the lab to the real world.
Our Human Sleep Lab is studying sleep’s impact on women’s health among other current themes. Sleep biology also explores medical neuroimaging advancements and preclinical sleep research.
Our biopharma R&D services dive deep into preclinical drug development. We also bring expertise in automated chemistry design; medicinal chemistry and synthesis; and licensable drugs.
We invent some of the world’s leading technology and tools to create new precision medicine possibilities: FOX Three Molecular Guidance System (MGS), DiaCyt, TALL, Techneins, and more.
Organizations work with SRI Biosciences to innovate around biomarker and biological assay development, biohazard detection devices, and health-monitoring wearables.
Real-world impact
-
Fiona Baker: Collaboration across teams is invaluable to my work
The director of SRI’s Center for Health Sciences works with other labs to solve sleep issues by integrating cutting-edge technologies.
-
SRI researchers identify a biomarker to target and treat pancreatic cancer
The cancer targeting molecule was discovered through SRI’s FOX Three Molecular Guidance System.
-
Menopause research in full swing at SRI
SRI’s Fiona Baker digs deep into how technology and peaceful behavior practices can help calm sleep during menopause.
Platforms
SRI Biosciences’ highly specialized platforms marry the advantages of our cutting-edge research with our flexible biotech business model. Partner with us to leverage our rigorous early discovery and development to customize your specific applications.
Cell-selective, intracellular delivery of macromolecular therapeutics: Deliver essentially any cargo to selected cell types, and internalize into those cells to targeted subcellular locations.
A new immunotherapy with the potential to overcome current challenges and extend the benefits of immunotherapy to many more patients.
Identification of peptide-based delivery agents that can selectively transport molecular cargos into the central nervous system without physically disrupting the blood-brain barrier.
A rapid discovery platform for non-natural polymers that expands our access to 3-dimensional structural diversity with the synthetic accessibility and optimizability of small molecules.
Recent publications
-
Association of the rs17782313, rs17773430 and rs34114122 Polymorphisms of/near MC4R Gene with Obesity-Related Biomarkers in a Spanish Pediatric Cohort
Our results highlight that metabolic risk factors, especially alterations in carbohydrate metabolism, were related to rs17782313.
-
Evaluation of a device-agnostic approach to predict sleep from raw accelerometry data collected by Apple Watch Series 7, Garmin Vivoactive 4, and ActiGraph GT9X Link in children with sleep disruptions
This study demonstrates that raw acceleration data from consumer wearable devices has the potential to be harnessed to predict sleep in children.
-
Bedtime screen use behaviors and sleep outcomes: Findings from the Adolescent Brain Cognitive Development (ABCD) Study
We aim to determine associations between bedtime screen time behaviors and sleep outcomes in a national study of early adolescents.